The manufacturer of ingenol mebutate (Picato®) has recalled all unexpired stock from wholesalers and pharmacies while investigations are ongoing into the concerns of the possible risk of skin malignancy.
Healthcare professionals are advised to:
- Stop supplying the above products immediately. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process
- Stop prescribing Picato and consider other treatment options as appropriate. For patients who have recently been prescribed Picato, advise patients to be vigilant for any skin lesions developing and to seek medical advice promptly should any occur
Action: Clinicians should be aware of this recall and investigation. Alternatives will need to be issued during the remainder of the investigation.
|« SMC Update - January 2020||Drug Safety Update - January 2020 »|